The aim of this study is to evaluate the effect of the study drug on patients with Implantable Cardioverter – Defibrillators (ICD) or Cardiac Resynchronization Therapy – Defibrillator (CRT-D.) The study will last approximately 3 years with visits every 12 weeks. This study will include blood draws, physical exams, vital signs, EKGs, ECHOs, urine collection, and study drug dispensing. All study related testing will be completed at no cost to the patient. Compensation may occur for qualified patients.
- Patient Population – Patients must have an ICD or CRT-D for primary or secondary prevention and must be hemodynamically stable.
- Sponsor – Gilead , St. Jude's Medical (Division of Cardiac Rhythm Management)
- Contact Information – (402) 384 – 2705, MPCHeartConsultantsResearch@nmhs.org
- View this study on ClinicalTrials.gov
This Study is Closed to Enrollment